Erythropoietin: still on the neuroprotection road
Therapeutic Advances in Neurological Disorders,
Subiros N et al. – A multicenter stroke trial where recombinant human erythropoietin (EPO) (rhEPO) was combined with recombinant tissue plasminogen activator (rtPA) had negative outcomes. The present paper reviews the EPO neuroprotective strategy and its mechanisms in ischemic stroke and in other human nervous system diseases.